XTL Biopharmaceuticals Ltd. (XTLB)

NASDAQ: XTLB · IEX Real-Time Price · USD

2.693

+0.053 (2.01%)

At close: May 17, 2024, 4:00 PM

2.790

+0.097 (3.60%)

After-hours: May 17, 2024, 5:38 PM EDT

2.01% (1D)

Market Cap	14.67M
Revenue (ttm)	n/a
Net Income (ttm)	-1.78M
Shares Out	5.45M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,539
Open	2.800
Previous Close	2.640
Day's Range	2.690 - 2.840
52-Week Range	0.750 - 4.990
Beta	1.03
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2018

About XTLB

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 1, 2005

Employees 8

Stock Exchange NASDAQ

Ticker Symbol XTLB

Full Company Profile